Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic Biotics, to improve patients’ lives. Synthetic Biotics are living probiotics that have been genetically engineered to perform specific functions in the GI
Ticker:
SYBX
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
PKU
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
